We create a better life through integrity and innovation.
We put patient and consumer well-being at the forefront of everything we do. Guided by cutting-edge scientific research and a focus on market needs, we continuously innovate to deliver exceptional quality in our products and services, improving lives worldwide.
News
Recently, GPN01530-2, an innovative FAP-targeted radiopharmaceutical developed by Grand Pharmaceutical Group Limited (00512.HK), was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA), becoming the world’s first FAP-targeted diagnostic RDC for solid tumors to receive FDA Fast Track Designation. The designation is primarily granted to investigational drugs intended to treat serious conditions and with the potential to address unmet medical needs, with the aim of accelerating the review process for high-value drug candidates.
On July 12, the 2026 (43rd) National Medicinal Industry Information Annual Conference was held in Beijing. At the conference, the China National Pharmaceutical Industry Information Center released the 2025 Top 100 Pharmaceutical Industrial Enterprises in China by Main Business Revenue. China Grand Enterprises, Inc. was once again included in the ranking, ranking fourth.
Grand Pharma’s subsidiary launched innovative dual‑mechanism nasal spray Ryaltris® in China, filling the clinical gap for allergic rhinitis combination therapies, especially for patients aged 6+. It enriches the firm’s respiratory portfolio and supports standardized, precise treatment while addressing high disease prevalence.
Focus
On November 3rd, the Ministry of Industry and Information Technology of China announced the list of National Technology Innovation Demonstration Enterprises for 2022. Grand Pharmaceuticals (China) Co., Ltd. (hereinafter referred to as “Grand Pharma”) was honored and…
On June 19, 2022, Grandpharma (0512.HK) announced that a "nuclear weapon" innovative medical product to treat liver malignant tumors -- SIR-Spheres® yttrium-90 microsphere injections (trademark in Chinese charters: 易甘泰®, read as “Yigantai”) …
On April 8, 2022, a new production base (West High-tech Zone) for blood products of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.("Yuanda Shuyang"), a wholly-owned subsidiary of Yuanda Life Science Group Co., Ltd, was officially put into operation,
Focus
On November 3rd, the Ministry of Industry and Information Technology of China announced the list of National Technology Innovation Demonstration Enterprises for 2022. Grand Pharmaceuticals (China) Co., Ltd. (hereinafter referred to as “Grand Pharma”) was honored and…
On June 19, 2022, Grandpharma (0512.HK) announced that a "nuclear weapon" innovative medical product to treat liver malignant tumors -- SIR-Spheres® yttrium-90 microsphere injections (trademark in Chinese charters: 易甘泰®, read as “Yigantai”) …
On April 8, 2022, a new production base (West High-tech Zone) for blood products of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.("Yuanda Shuyang"), a wholly-owned subsidiary of Yuanda Life Science Group Co., Ltd, was officially put into operation,
Group
Our growth is driven by regulatory compliance, operational excellence, and an enduring commitment to life-changing breakthroughs.
Businesses
Innovation is the key driver of our growth. Aligned with strategic objectives and focused on our core business areas, we build our competitive edge on responsibility and a commitment to progress.